Phase I assessment of the pharmacokinetics, metabolism, and safety of emitefur in patients with refractory solid tumors

Journal of Clinical Oncology

Volumn 18, Issue 19, 2000, Pages 3423-3434

  Nemunaitis, J ^a   Eager, R ^a   Twaddell, T ^a   Corey, A ^a   Sekar, K ^a   Tkaczuk, K ^a   Thompson, J ^a   Hoff, P M ^a   Pazdur, R ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; EMITEFUR; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; INTERFERON; INTERLEUKIN 2; IRINOTECAN; LEDOXANTRONE; MELPHALAN; METHOTREXATE; MITOMYCIN; PACLITAXEL; TAMOXIFEN; TOPOTECAN; VINBLASTINE; VINCRISTINE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE CALCULATION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; MALE; MAXIMUM PERMISSIBLE DOSE; MOUTH DISEASE; NEPHROTOXICITY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; TREATMENT OUTCOME;

EID: 0034306322     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.19.3423     Document Type: Article

References (46)

1. Oral administration of BOF-A2 to rats with lung transplanted tumors results in increased 5-FU levels
2. Antitumor activity of BOF-A2, a new 5-fluorouracil derivative
3. Leukopenia-induced effect of a combination of a new 5-fluorouracil (5-FU)-derived drug, BOF-A2 (emitefur), with other 5-FU-derived drugs or BV-araU (sorivudine) in rats
4. The inhibitory action of BOF-A2, a 5-fluorouracil derivative on squamous cell carcinoma
5. 3-Cyano-2,6-dihydroxy-pyridine (CNDP), a new potent inhibitor of dihydrouracil dehydrogenase
6. Effects of the plasma concentration of 5-FU and the duration of continuous venous infusion of 5-FU with an inhibitor of 5-FU degradation on Yoshida sarcomas in rats
7. Pharmacokinetic modulation of plasma 5-FU concentrations to potentiate the antitumor activity of continuous venous infusion of 5-FU
8. Efficacy of a new 5-FU derivative, BOF-A2 in advanced non-small cell lung cancer
9. Reporting results of cancer treatment
10. A phase III study comparing the clinical utility of four regimens of 5-FU
11. Antimetabolites in cancer
12. Developments of fluoropyrimidine therapy for gastrointestinal cancer
13. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer
14. Toxicity of fluorouracil in patients with advanced colorectal cancer: Effect of administration schedule and prognostic factors
15. Randomized phase II noncomparative trial of oral and intravenous doxifluridine plus levo-leucovorin in untreated patients with advanced colorectal carcinoma
16. Pharmacokinetic studies of 5-FU after oral and intravenous administration in man
17. Fluoropyrimidines: A critical evaluation
18. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: Population characteristics, newly identified deficient patients, and clinical implication in 5-FU chemotherapy
19. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal cancer: A Mid-Atlantic Oncology Program Study
20. Pharmacokinetics of 5-FU administration orally, by rapid intravenous and by slow infusion
21. 120-Hour 5-FU continuous infusion plus BCNU in advanced colorectal cancer
22. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer
23. Phase II study of 5-FU and its modulation in advanced colorectal cancer: A Southwest Oncology Group (SWOG) Study
24. Effects of 5-FU derivative UFT on thymidylate synthetase and thymidine kinase in rat colorectal tumors
25. Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites
26. Capecitabine
27. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts
28. Phase I and pharmacologic study of intermittent twice daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer
29. Infusional 5-fluorouracil in breast cancer
30. 5-Fluorouracil by protracted venous infusion: A review of recent clinical studies
31. Activity of continuous infusion 5-fluorouracil in patients with advanced colorectal cancer clinically resistant to bolus 5-fluorouracil
32. Phase II trial of uracil and tegafur plus oral leucovorin: An effective oral regimen in the treatment of metastatic colorectal carcinoma
33. Phase II trial of UFT in advanced colorectal and gastric cancer
34. Randomized trial of adjuvant chemotherapy with mitomycin plus ftorafur versus mitomycin alone in resected locally advanced gastric cancer
35. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-FU selectively in tumors by enzymes concentrated in human liver and cancer tissue
36. Relationship between dihydropyrimidine dehydrogenase activity and 5-FU levels with evidence of circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-FU
37. 5-Fluoropyrimidines
38. Prolonged venous infusion (PVI) of 5-FU for metastatic colon cancer (MCC): A follow-up report
39. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer
40. Phase I and pharmacokinetic study of oral UFT, a combination of the 5-fluorouracil prodrug tegafur and uracil
41. Phase I and pharmacokinetic (PK) study of the novel oral fluoropyrimidine, S-1
42. Mechanism-based inactivation of dihydropyrimidine dehydrogenase by 5-ethynyluracil
43. Pharmacokinetics, oral bioavailability and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase
44. 5-Ethynyluracil (776C85): A potent modulator of the pharmacokinetics and antitumor efficacy of 5-FU
45. A phase II open-lable study to evaluate a 28-day regimen of oral 5-FU plus 776C85 for the treatment of patients with previously untreated metastatic colorectal cancer